Ross Levinsohn, the interim CEO who was snubbed in the search for a permanent leader at Yahoo, is leaving the Internet portal.
Yahoo announced the departure in a securities filing Monday.
With much fanfare, Yahoo appointed 37-year-old Marissa Mayer as CEO two weeks ago. Retaining Levinsohn would have been one of her first big triumphs.
Levinsohn, 48, had been head of Yahoo’s global media business and had pushed the company to enter into exclusive partnerships with the likes of CNBC and Tom Hanks to create original content.
But Levinsohn was passed over twice by the company’s board in favor of other top executives, including Scott Thompson, who resigned in May over discrepancies on his resume after just four months on the job.
Old National Bancorp on Monday reported second-quarter earnings of $27.2 million, or 29 cents per diluted common share, a 60 percent jump from the $17.0 million, or 18 cents a share posted for the same three months of 2011.
The Evansville-based parent of Old National Bank had several highlights during the quarter, President and CEO Bob Jones said.
“Organic loan growth, sound expense management, better-than-peer credit quality and an expanding net interest margin are the result of a continued focus on our strategic imperatives as well as our ability to be a successful acquirer,” he said in a written statement.
Among the company’s acquisitions in the past two years are Integra Bank and Monroe Bancorp. Old National’s acquisition of Indiana Community Bancorp, announced Jan. 25, is pending.
General Motors Co. says that its global chief marketing officer, Joel Ewanick, has resigned from the Detroit automaker. The announcement comes after several major changes to the company’s advertising approach and just ahead of its second-quarter earnings report Thursday.
GM said Sunday that Ewanick had elected to resign and his decision takes effect immediately. The 52-year-old executive joined the company in 2010 to oversee marketing for the company’s North American unit and was promoted within months to head its global marketing business.
Genetic test maker 23andMe is asking the Food and Drug Administration to approve its personalized DNA test in a move that could boost acceptance of technology that is viewed skeptically by leading scientists.
23andMe is part of a fledgling industry that allows consumers to peek into their genetic code for details about their ancestry and future health. The company’s saliva-based kits have attracted scrutiny for claiming to help users detect whether they are likely to develop illnesses like breast cancer, heart disease and Alzheimer’s.